This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slattery, M. L. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Slattery, M. L. Articles by Potter, J. D.

Transcription Factor 7–like 2 Polymorphism and Colon Cancer

¹ Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah; ² Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota; ³ Kaiser Permanente Medical Research Program, Oakland, California; and ⁴ Fred Hutchinson Cancer Research Center, Seattle, Washington

Requests for reprints: Martha L. Slattery, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108. Phone: 801-585-6955; Fax: 801-581-3623. E-mail: mslattery{at}hrc.utah.edu

Polymorphisms of the transcription factor 7–like 2 (TCF7L2) gene have been associated with insulin sensitivity and diabetes, and the TCF7L2 gene is involved in the Wnt/β-catenin signaling pathway, all factors thought to be important in the etiology of colon cancer. In this confirmatory study, we evaluated the rs7903146 TCF7L2 polymorphism with colon cancer using previously collected data on 1,578 cases and 1,966 controls. We did not observe a statistically significant association between the rs7903146 polymorphisms and risk of colon cancer [odds ratio (OR), 1.12; 95% confidence interval (95% CI), 0.98-1.28] when evaluating the total population. We did, however, observe a statistically significant interaction between the rs7903146 TCF7L2 polymorphism and recent use of aspirin/nonsteroidal anti-inflammatory drugs (NSAID; P = 0.001). Increased colon cancer risk associated with the T allele was restricted to those without recent use of aspirin/NSAIDs (OR, 1.65; 95% CI, 1.35-2.02, relative to recent aspirin users, i.e., use of aspirin/NSAIDS within the 2 years before diagnosis, with the CC genotype). Among individuals who reported recent use of aspirin/NSAIDs, the T allele reduced risk of colon cancer (OR, 0.78; 95% CI, 0.62-0.98) in a dose-response fashion (P for linear trend across genotypes = 0.03). These data suggest that colon cancer risk associated with the rs7903146 TCF7L2 polymorphism is modified by use of aspirin/NSAIDs. (Cancer Epidemiol Biomarkers Prev 2008;17(4):978–82)

This article has been cited by other articles:

				J. Flint and T. F.C. Mackay Genetic architecture of quantitative traits in mice, flies, and humans Genome Res., May 1, 2009; 19(5): 723 - 733. [Abstract] [Full Text] [PDF]

				G. da Silva Xavier, M. K. Loder, A. McDonald, A. I. Tarasov, R. Carzaniga, K. Kronenberger, S. Barg, and G. A. Rutter TCF7L2 Regulates Late Events in Insulin Secretion From Pancreatic Islet {beta}-Cells Diabetes, April 1, 2009; 58(4): 894 - 905. [Abstract] [Full Text] [PDF]

				T. Jin and L. Liu Minireview: The Wnt Signaling Pathway Effector TCF7L2 and Type 2 Diabetes Mellitus Mol. Endocrinol., November 1, 2008; 22(11): 2383 - 2392. [Abstract] [Full Text] [PDF]

				A. L. George Jr. Appraising the Value of Genomic Association Studies J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1840 - 1842. [Full Text] [PDF]